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Abstract
Objective—To report the clinical characteristics of 12 patients with limbic encephalitis (LE) who 
were antibody-negative after a comprehensive immunological study.
Methods—Review of clinical records of 163 patients with LE. Immunohistochemistry on rat 
brain, cultured neurons, and cell-based assays were used to identify neuronal autoantibodies. 
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Patients were included if 1) there was adequate clinical, CSF, and MRI information to classify the 
syndrome as LE, 2) MRI images were accesible for central review, and 3) serum and CSF were 
available and confirmed negative for neuronal antibodies.
Results—Twelve (7%)/163 LE patients (median age: 62 years; range: 40–79; 9 [75%] male) 
without neuronal autoantibodies were identified. The most frequent initial complaints were deficits 
in short-term memory leading to hospital admission in a few weeks (median time: 2 weeks; range: 
0.5–12). In four patients the short-term memory dysfunction remained as isolated symptom during 
the entire course of the disease. Seizures, drowsiness, and psychiatric problems were unusual. Four 
patients had solid tumors (1 lung, 1 esophagus, 2 metastatic cervical adenopathies of unknown 
primary tumor) and 1 chronic lymphocytic leukemia. CSF showed pleocytosis in 7 (58%) with a 
median of 13 white blood cells/mm3 (range: 9–25). Immunotherapy included corticosteroids, 
intravenous immunoglobulins, and combinations of both drugs or with rituximab. Clinical 
improvement occurred in 6 (54%) of 11 assessable patients.
Conclusions—Despite the discovery of new antibodies, 7% of LE remains seronegative. 
Antibody-negative LE is more frequent in older males and usually develops with predominant or 
isolated short-term memory loss. Despite the absence of antibodies, patients may have an 
underlying cancer and respond to immunotherapy.
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Introduction
Limbic encephalitis (LE) is a well characterized neurological syndrome that usually has an 
autoimmune etiology.1 Although the term LE is frequently misused to identify any type of 
paraneoplastic encephalitis or patients with isolated epilepsy and enlarged hippocampus,2 
recently proposed criteria emphasize the combination of clinical and imaging features for its 
diagnosis.1 Symptoms of LE present with a subacute onset, usually in weeks, including 
confusion, short-term memory loss, behavioral changes, and often seizures. The CSF 
presents mild to moderate lymphocytic pleocytosis (usually <100 white blood cells 
(WBC)/mm3) in 60–80% of the patients, and the MRI shows increased FLAIR/T2 signal in 
the medial aspect of one or both temporal lobes.1 When bilateral involvement occurs the 
diagnosis of definite autoimmune LE can be made even in the absence of neuronal 
antibodies provided that other alternative causes are reasonably excluded.1
Although the recent characterization of novel antibodies against cell surface and synaptic 
antigens3 has changed the diagnostic and treatment approach to LE and proved that 
previously seronegative cases were indeed associated with neuronal autoantibodies, there is 
no data on the frequency and clinical characteristics of patients with autoimmune LE that 
remain antibody negative. The recognition of these patients is important in an era that over-
relies on antibody testing for the diagnosis of neurological syndromes of autoimmune origin.
In the present study we report the clinical features of 12 patients with autoimmune LE that 
were antibody-negative after comprehensive immunological investigations.
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We reviewed the clinical information of 163 patients with clinical and MRI features of LE 
and whose serum and CSF were sent for antibody testing to the laboratory of Hospital Clinic 
(Barcelona, Spain) between January 2000 and June 2017. Patients included in the study 
fulfilled the following criteria: 1) adequate clinical, CSF, EEG, and MRI information to 
classify the syndrome as LE, 2) MRI studies available for central review by an experienced 
neuroradiologist, and 3) serum and CSF available for antibody testing which turned out 
negative for known antibodies and on cultures of live hippocampal neurons (see below). LE 
was considered paraneoplastic when a tumor was diagnosed within 5 years of onset of 
neurological symptoms.4
Written informed consent for the storage and use of samples for research was obtained from 
patients or representative family members. The study was approved by the internal review 
board of the Hospital Clínic, Barcelona, Spain.
Detection of antineuronal antibodies and screening for novel cell surface autoantigens
All serum and CSF samples were examined for onconeural antibodies (Hu, Yo, Ri, CV2 
(CRMP5), amphiphysin, Ma1, Ma2, Tr (DNER), Zic4, and SOX1), GAD, AK5, and cell 
surface antibodies (NMDAR, AMPAR, GABAAR, GABABR, IgLON5, CASPR2, LGI1, 
DPPX, neurexin 3α, mGluR1, and mGluR5) using reported techniques.3–7 Samples were 
also examined for antibodies to unknown neuronal antigens using immunohistochemistry on 
rat brain either post-fixed or perfused with paraformaldehyde and immunofluorescence on 
cultured live hippocampal neurons and HEK293 cells transfected with the appropriate 
antigens, as reported.5–8
Results
We identified 12 (7%) antibody-negative patients out of 163 with LE. The remaining 151 LE 
were antibody-positive (LGI1: 71, GABAbR: 26, Ma2: 13, AMPAR: 12, Hu: 11, CASPR2: 
10, SOX1: 3, AK5:2, mGluR5:1, amphiphysin: 1, neurexin 3α: 1). Predominant clinical 
features, response to immunotherapy and outcome at the last visit of the 12 antibody-
negative LE patients are summarized in Table 1. Median age was 62 years (range: 40–79 
years) and 9 (75%) were male. A tumor was identified in 5 (42%) patients. All but one 
tumor were diagnosed several months after the onset of LE (Table 1). Other comorbidities 
were rare; one patient (Patient 6, table 1) had heart transplantation 11 years before the onset 
of LE and she was on low doses of steroids and mycophenolate at the time of diagnosis. 
Prodromal symptoms were reported by 6 (50%) patients and included mild flu-like 
symptoms, nausea and vomiting or diarrhea and in one patient, episodes of high fever during 
the 5 months preceding the onset of LE (Table 1).
The most common initial complaints were deficits in short-term memory along with 
temporal disorientation and confusion that lead to hospital admission in a few weeks 
(median time 2 weeks; range: 0.5–12). In four (33%) patients the short-term memory 
dysfunction was the most relevant symptom that remained isolated throughout the course of 
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the disease. Unlike other types of LE, seizures, drowsiness, or psychiatric problems were 
unusual. Only 1 (8%) patient had seizures that did not occur at the onset of the disease nor 
were severe or frequent in number. Two patients complained of visual hallucinations and one 
developed a Klüver-Bucy syndrome but the remaining 9 (75%) patients did not develop 
behavior or personality/mood changes like agitation, anxiety, depression or full-blown 
psychosis.
By definition, brain MRI T2/FLAIR abnormalities involving both hippocampi were found in 
all patients. In addition, 4 (33%) of them had involvement of the insula, frontoorbitary 
cortex or basal ganglia. CSF pleocytosis (≥ 5 WBC/mm3) was observed in 7 (58%) patients 
with a median of 13 WBC/mm3 (range: 9–25). EEG was abnormal in 10 (83%) patients, 
showing focal or diffuse slowing without associated epileptiform discharges. Only two 
patients had a normal EEG and no CSF pleocytosis. Other causes of LE were reasonably 
excluded: PCR for herpes viruses was negative in the CSF, there was no clinical history or 
laboratory evidence of systemic autoimmune disorders, neurosyphilis or Whipple disease, 
and anti-thyroid antibodies were negative. Lastly, the follow-up excluded CNS malignancies 
or neurodegenerative diseases.
Immunotherapy (Table 1) included intravenous corticosteroids or immunoglobulins in all 
patients either alone (7 patients), combinations of both drugs (3), or with rituximab (2). 
Clinical improvement occured 6 (54%) of 11 assessable patients. Autopsy was granted in 
patient 9 (table 1) who died from complications of a massive stroke. In the contraleteral 
cerebral hemisphere analysis of the hippocampus disclosed perivascular and parenquimatous 
infiltrates with neuronal loss and gliosis. Immunohistochemical studies showed numerous 
CD8+ T cells that were frequently located in close proximity to neurons (Figure 1).
Discussion
This study demonstrates that despite new techniques for antibody detection and the recently 
identified large repertoire of antibodies against neuronal cell surface antigens there is a 
subgroup of autoimmune LE that remains antibody-negative.9 The frequency of 7% is not 
very different from that of 11% identified in our previous study in 2008 when we started to 
identify antibodies against surface antigens in LE.10 Our findings also support the recent 
proposed criteria for definite LE which do not require the demonstration of neuronal 
antibodies provided that patients have a subacute clinical (< 3 months) presentation of short-
term memory deficit, seizures, or psychiatric symptoms, bilateral MRI FLAIR/T2 
abnormalities predominantly involving the medial temporal lobes, and either CSF 
pleocytosis (WBC >5/mm3) or EEG with epileptic or slow activity involving the temporal 
lobes.1
Previous studies on seronegative LE included isolated case reports with incomplete 
immunological studies, for example published before the description of antibodies closely 
associated with LE such as GABAB-receptor antibodies, LE associated with systemic 
autoimmune disorders, or resulting from immunological adverse effects of immune check-
point inhibitors.11–18
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Although our patients did not have distinctive clinical features compared with reported 
antibody-positive LE, a few issues must be emphasized. The main clinical presentation was 
rapid, in a few weeks, and included cognitive dysfunction with prominent short-term 
memory deficits and disorientation. Drowsiness, seizures, and severe behavioral changes, 
commonly observed in antibody-positive LE, were rarely described. The frequency of 
seizures for example is >50% in series of antibody-positive LE a figure much lower than the 
8% found in the present study.19–21 This clinical presentation is similar to that seen in LE 
and AK5 antibodies, a non-paraneoplastic LE that occurs in older patients (median age 64 
years) and, as in our patients, may present with isolated anterograde amnesia.22 Antibody-
negative LE may be paraneoplastic but the associated tumors (Table 1) differ from those 
commonly seen in antibody-positive LE (e.g., small-cell lung cancer and Hu or GABAbR 
antibodies; testicular cancer and Ma2 antibodies). Therefore, the presence of an underlying 
tumor in 42% of our patients emphasizes the need for tumor screening in LE patients 
without neuronal autoantibodies.
The term antibody-negative, or seronegative, LE has been used to describe a subgroup of 
patients with temporal lobe epilepsy and MRI evidence of enlarged amygdala or 
hippocampus in FLAIR/T2 sequences who did not have neuronal antibodies.2 As defined in 
our series, LE includes a set of clinical and MRI criteria that are almost never fulfilled by 
patients who present with isolated epilepsy. In fact, we observed that antibody negative LE 
patients rarely develop seizures as part of the clinical syndrome. An important 
terminological problem also seems to apply to patients considered to have LE as the trigger 
of temporal lobe epilepsy with hippocampal sclerosis. Although LE may in some cases lead 
to hippocampal sclerosis, many of the reported patients had unilateral or chronic, 
asynchronous involvement of the hippocampi (sometimes months or years apart), presenting 
with seizures and with clinical features and disease course different from those included in 
the criteria of LE.23,24 In our opinion the use of the term LE in these patients is misleading 
and we favor the proposed alternative name of temporal lobe epilepsy with amygdala 
enlargement of autoimmune origin.25
A limitation of our study is that it does not provide a biomarker to confirm that antibody-
negative LE is indeed autoimmune and the underlying mechanisms involved. In one of our 
paraneoplastic patients the neuropathological findings suggested that at least in some cases, 
the LE could be T-cell mediated as proposed for LE associated with onconeural antibodies.
26 On the other hand, immunotherapy was beneficial in 50% of our patients suggesting that 
potentially undetected antibodies could be responsible for the syndrome. The fact that 75% 
of the patients were older men raises the possibility that some could have had low titer LGI1 
antibodies undetectable by current tests. However, this is unlikely because the clinical profile 
of patients with anti-LGI1 LE is different, with high frequency of different types of seizures, 
often preceded by faciobrachial dystonic seizures, and hyponatremia.21,27 We cannot rule 
out the possibility of yet unknown antibodies which may be undetectable with the 
techniques used here. For example, Lambert-Eaton myasthenic syndrome is caused by 
antibodies against P/Q type voltage gated calcium channels. These antibodies are determined 
by radioimmunoassay but they are undetectable by immunohistochemical or 
immunocytochemical techniques used in our study.28
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Overall, the current findings along with the reported clinical and MRI criteria for LE,1 
demonstrate the occurrence of antibody negative LE of possible autoimmune etiology. 
Importantly, patients with this disorder may have cancer but more than 50% had substantial 
neurological improvement after immunotherapy. This type of LE is more frequent in older 
males and usually presents with predominant or isolated short-term memory loss. The task 
for future studies is to determine whether these patients have autoantibodies that are 
undetectable with current methods.
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Brain MRI and neuropathological findings in a patient with antibody-negative LE and 
adenocarcinoma of the lung. Panel A, axial FLAIR showing high signal intensity in both 
hippocampi and gyrus recti. Panel B, hematoxylin and eosin staining of hippocampus 
demonstrating perivascular and parenchymatous inflammatory infiltrates. 
Immunohistochemical analysis showed many CD8+ T cells in the parenchyma (Panel C) and 
in close apposition with neurons (Panel D). Panels C and D lightly counterstained with 
hematoxylin. Positive CD8 T cells are stained brown.
Graus et al. Page 8


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eur J Neurol. Author manuscript; available in PMC 2019 August 01.
